Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nutritional Therapy Plus Glucocorticoid for Immune Checkpoint Inhibitor-Related Pneumonitis
NCT07554885Not yet recruiting
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Randomised, open-label trial in Immune checkpoint inhibitor-related pneumonitis (CIP) (2 arms), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoints: Time to immune-related pneumonitis downgrading up to 6 months and Proportion of participants with pneumonitis downgrading at 3 months. Planned start Apr 2026; status: not yet recruiting.
02
Conditions
Immune checkpoint inhibitor-related pneumonitis (CIP)
Beyond the preview
Go deeper on NCT07554885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554885.